Neumora Therapeutics, Inc. (NMRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $80.59M
Last updated: Nov 17, 2026 at 11:03 AM ET
Neumora Therapeutics, Inc. (NMRA) Financials: Revenue, Profit and Cash Flow
Neumora Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$236.93M, operating cash flow was -$206.44M and free cash flow was -$206.44M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$34.44M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $241.16M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $1.55M | N/A | N/A |
| Gross profit | $0 | $0 | $0 | $0 | -$1.55M | N/A | N/A |
| Research and development | $181.06M | $200.93M | $206.62M | $104.75M | $212.78M | $87.13M | $0 |
| Operating income | -$241.16M | -$263.46M | -$252.10M | -$135.87M | -$237.32M | -$95.52M | N/A |
| Net income | -$236.93M | -$243.79M | -$235.93M | -$130.90M | -$237.31M | -$99.27M | N/A |
| EBITDA | N/A | -$262.91M | -$251.60M | -$134.87M | -$236.77M | -$95.41M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 | -$166.00K |
| Operating income | -$33.41M | -$42.19M | -$52.86M | -$58.48M | -$57.70M | -$54.04M | -$70.94M | -$62.92M | -$76.65M | -$63.82M | -$60.07M | -$114.00M |
| Net income | -$34.44M | -$43.08M | -$53.46M | -$59.45M | -$56.76M | -$52.73M | -$67.99M | -$58.82M | -$72.55M | -$58.70M | -$53.72M | -$108.73M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $54.82M by $127.71M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $191.05M | $316.97M | $496.19M | $426.23M | $429.30M | $197.95M | $0 |
| Current assets | $190.54M | $314.06M | $478.28M | $387.95M | $415.60M | $193.84M | $0 |
| Cash and equivalents | $182.53M | $142.15M | $374.04M | $240.94M | $409.25M | $191.98M | $0 |
| Total liabilities | $87.18M | $29.91M | $27.12M | $29.40M | $754.52M | $292.33M | $21.00K |
| Short-term debt | $284.00K | $1.85M | $3.38M | $3.37M | $1.06M | $764.00K | N/A |
| Long-term debt | $54.53M | $0 | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $103.87M | $287.06M | $469.08M | -$446.85M | -$325.22M | -$94.38M | -$21.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $95.05M | $125.25M | $153.88M | $191.05M | $177.83M | $223.82M | $256.75M | $316.97M | $352.54M | $404.47M | $450.21M | $496.19M |
| Total liabilities | $76.50M | $80.73M | $83.20M | $87.18M | $45.67M | $40.95M | $28.38M | $29.91M | $31.80M | $23.21M | $25.67M | $27.12M |
| Cash and equivalents | $85.65M | $116.83M | $147.07M | $182.53M | $129.07M | $124.52M | $126.86M | $142.15M | $275.71M | $150.68M | $182.93M | $374.04M |
| Shareholder equity | $18.55M | $44.52M | $70.68M | $103.87M | $132.16M | $182.88M | $228.36M | $287.06M | $320.74M | $381.26M | $424.54M | $469.08M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$206.44M | -$182.94M | -$163.28M | -$114.90M | -$75.42M | -$26.76M | -$26.76M |
| Capital expenditures | $0 | $0 | $117.00K | $511.00K | $817.00K | $1.30M | $1.30M |
| Free cash flow | -$206.44M | -$182.94M | -$163.40M | -$115.41M | -$76.24M | -$28.06M | -$28.06M |
| Investing cash flow | $168.52M | -$70.56M | $64.39M | -$168.01M | -$817.00K | -$11.24M | -$11.24M |
| Financing cash flow | $77.09M | $21.60M | $231.94M | $115.74M | $293.51M | $230.10M | $230.10M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.44M | -$39.53M | -$46.40M | -$47.95M | -$46.63M | -$52.40M | -$59.45M | -$50.34M | -$33.48M | -$56.16M | -$42.95M | -$51.44M |
| Capital expenditures | N/A | N/A | $0 | $16.00K | $16.00K | $0 | $0 | $0 | $775.00K | $0 | $775.00K | $44.00K |
| Free cash flow | N/A | N/A | -$46.40M | -$47.97M | -$46.65M | -$52.40M | -$59.45M | -$50.34M | -$34.26M | -$56.16M | -$43.73M | -$51.49M |
Frequently Asked Questions About NMRA
What is Neumora Therapeutics' annual revenue?
Neumora Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Neumora Therapeutics profitable?
No. Neumora Therapeutics reported net income of -$236.93M for the fiscal year ended Dec 31, 2025.
How much free cash flow does NMRA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$206.44M minus capital expenditures of $0 produced free cash flow of -$206.44M.
How much debt does Neumora Therapeutics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $54.53M, short-term debt of $284.00K and cash and equivalents of $182.53M.
NMRA pages: Overview, Earnings, Forecast, Financials, Competitors